Andere Sprachen Revelation Biosciences, Inc.

Aktien

A401N4

US76135L5075

REVB

Verzögert Nasdaq Andere Börsenplätze 20:59:05 15.05.2024			% 5 Tage	% 1. Jan.
1,98 ^USD	+7,32 %		-11,21 %	-86,82 %

10.05.	Revelation Biosciences, Inc. meldet Ergebnis für das erste Quartal zum 31. März 2024	CI
22.03.	Revelation Biosciences, Inc. meldet Ergebnis für das vierte Quartal zum 31. Dezember 2023	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Revelation Biosciences, Inc. Announces Financial Results for the Three Months Ended March 31, 2024	10.05.
Revelation Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	10.05.
Revelation Biosciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	22.03.
Revelation Biosciences, Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2023	22.03.
Revelation Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	22.03.
Revelation Biosciences Inc. Gives Oral Presentation at Advances in Critical Care Nephrology (AKI & CRRT 2024)	13.03.
Revelation Biosciences Inc. to Participate in a Virtual Fireside Chat at the 36th Annual Roth Conference	12.03.
Revelation Biosciences Inc. Announces Commencement of First in Human Phase 1 Clinical Study of Gemini	04.03.
Revelation Biosciences Inc. Announces Commencement of First in Human Phase 1 Clinical Study of Gemini	04.03.
Revelation Biosciences Inc. Receives Invitation to Give an Oral Presentation at The 29th International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2024)	13.02.
Revelation Biosciences : Announces Commencement of First in Human Phase 1 Clinical Study of Gemini	13.02.
Thinking about buying stock in Meta Platforms, Ocular Therapeutix, Phathom Pharmaceuticals, Revelation Biosciences, or Sunworks?	12.02.
Revelation Biosciences Inc. Announces Closing of $6.2 Million Public Offering	05.02.
Top Midday Decliners	01.02.
Exchange-Traded Funds Higher, Equity Futures Mixed Pre-Bell Thursday on Unchanged Fed Rate, Upcoming Earnings	01.02.
Top Premarket Decliners	01.02.
Revelation Biosciences Inc. Announces Pricing of $6.2 Million Public Offering	01.02.
Thinking about buying stock in Guardion Health Sciences, Minim, Revelation Biosciences, Nyxoah, or Pixelworks?	31.01.
Top Premarket Gainers	31.01.
Revelation Biosciences Inc. to Present at The International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2024)	30.01.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Revelation Biosciences, Inc.

Aktien

A401N4

US76135L5075

REVB

Andere Sprachen

Filter